DUBLIN--(BUSINESS WIRE)--The "Investigation Report on China's Omalizumab Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Omalizumab, developed by Novartis Europharm, is the only approved antibody designed to target and block immunoglobulin E (IgE).

The analyst predicts that with the increase in the number of indications, the sales of Omalizumab in China will continue to grow from 2021 to 2025.

China is one of the countries with the highest mortality rate of asthma in the world. In 2020, there were about 30 million asthma patients in China, which was 1.5 times higher than the number of patients in 2017 (20 million). Therefore, it can be speculated that the number of indications of Omalizumab in China will continue to grow and sales will increase accordingly.

Omalizumab is clinically more accurate and more effective than inhaled corticosteroids and long-acting inhaled �2-adrenergic receptor agonists, especially for patients with moderate to severe asthma. Based on these therapeutic advantages, the market share of Omalizumab will increase in the future.

In addition, Omalizumab has only been approved for one indication in China, and 4 indications have been approved globally. Therefore, the number of approved indications for Omalizumab in China still has potential for growth. It can be predicted that its sales will continue to grow with the expansion of the market and the increase of the number of indications in the future.

At the end of 2017, the FDA approved the registration of Novartis Europharm ' Omalizumab, which will enter the field of anti-COPD and moderate to severe persistent allergic asthma. Since then, Omalizumab has been officially launched in China. Omalizumab is the only monoclonal antibody currently on the market in China for the treatment of asthma. By the first half of 2021, Novartis Europharm is the only manufacturer in the Chinese Omalizumab market.

According to the market research, Omalizumab sales have increased year by year from 2018 to 2020. At the beginning of 2020, Omalizumab was included in China's medical insurance as a treatment for respiratory diseases.

During the period of the COVID-19 epidemic, the sales of Omalizumab has increased. Therefore, its sales value reached CNY41.61 million in China in 2020, with an annual growth rate of 281.5%. The CAGR of Omalizumab's sales value in the Chinese market from 2018 to 2020 is 163.2%.

Topics Covered:

• The impact of COVID-19 on China's Omalizumab market
• Sales value of China's Omalizumab 2016-2020
• Competitive landscape of China's Omalizumab market
• Prices of Omalizumab in China
• Prices of Omalizumab in China by regions and manufacturers
• Analysis of factors affecting the development of China's Omalizumab market
• Prospect of China's Omalizumab market from 2021 to 2025

Key Topics Covered:

1 Relevant Concept of Omalizumab

1.1 Indications for Omalizumab

1.2 Development of Omalizumab in China

1.3 Governmental Approval of Omalizumab in China

1.4 The Impact of COVID-19 on Omalizumab sales in China

2 Sales of Omalizumab in China, 2018-2020

2.1 Sales Value of Omalizumab

2.1.1 Overall Sales Value

2.1.2 Sales Value by Region

2.2 Sales Volume of Omalizumab

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 Sales of Omalizumab by Dosage Form in China, 2018-2020

2.3.1 Injection

2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Omalizumab Manufacturers in China, 2018-2020

3.1 Analysis of Market Share of Major Omalizumab Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales volume

3.2 Novartis Europharm

3.2.1 Enterprise Profile

3.2.2 Sales of XOLAIR (Novartis Europharm's Omalizumab) in China

4 Prices of Omalizumab for Different Manufacturers in China, 2020-2021

4.1 Novartis Europharm (XOLAIR)

4.2 Analysis of Other Enterprises

5 Prospect of Chinese Omalizumab drug Market, 2021-2025

5.1 Influential Factors of Chinese Omalizumab Market Development

5.1.1 The Impact of COVID-19 on Chinese Omalizumab Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

List of Charts

Chart Patent Information About Omalizumab Injection Registration in China

Chart Sales Value of Omalizumab Injection over the World

Chart Sales Value of Omalizumab Injection in China, 2018-2020

Chart Sales Value of Omalizumab Injection in China by Region, 2018-2020

Chart Sales Volume of Omalizumab Injection in China, 2018-2020

Chart Sales Volume of Omalizumab Injection in China by Region, 2018-2020

Chart Market Share by Sales Value of Top Omalizumab Manufacturers in China, 2018-2020

Chart Sales Value and Volume of XOLAIR in China, 2018-2020

Chart Referential Prices of XOLAIR in China, 2020-2021

Chart Forecast on Sales Value of Omalizumab in China, 2021-2025

Chart Forecast on Sales Volume of Omalizumab in China, 2021-2025

For more information about this report visit https://www.researchandmarkets.com/r/74qnp1

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900